Bone Marrow Transplantation Market Report 2025

The bone marrow transplantation market size has grown strongly in recent years. It will grow from $11.61 billion in 2024 to $12.23 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increasing prevalence of hematologic disorders, improved healthcare infrastructure, rising awareness and education, aging population, government initiatives and support.

The bone marrow transplantation market size is expected to see strong growth in the next few years. It will grow to $15.25 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to advancements in immunotherapy, increasing demand for allogeneic transplants, expanding applications in non-hematologic diseases, personalized medicine and precision therapeutics, global collaboration, and partnerships. Major trends in the forecast period include technological advancements, increasing demand for allogeneic transplants, rising applications in non-malignant diseases, emergence of car-t cell therapies, enhanced pre-transplant diagnostics.

The anticipated surge in cancer and disease cases is expected to drive the expansion of bone marrow transplantation procedures. With cancer being a condition characterized by rapid and uncontrolled cell reproduction, bone marrow transplants emerge as a crucial treatment method. By replacing diseased bone marrow with healthy cells, these transplants offer a promising avenue for addressing the escalating incidences of cancer and other ailments. In 2022, reports from the American Cancer Society Inc. estimated approximately 1.9 million new cancer cases in the US, resulting in an anticipated 609,360 cancer-related deaths. This underscores the pressing need for advancements in bone marrow transplantation, aligning with the rising prevalence of diseases.

The burgeoning field of cell therapy trials is poised to significantly impact the landscape of bone marrow transplantation. These trials, focused on assessing the viability and safety of utilizing living cells to treat various medical conditions, heavily rely on bone marrow transplantation for its capacity to supply vital hematopoietic stem cells. These cells are instrumental in replacing damaged cells, addressing blood disorders, and pioneering innovative cell-based therapies for diverse ailments. Notably, data from the American Society of Gene & Cell Therapy in January 2023 highlighted a 7% growth in the gene, cell, and RNA therapy pipeline from preclinical to pre-registration in 2022, totaling 3,726 therapies in development. This reinforces the projected influence of cell therapy trials on propelling advancements in bone marrow transplantation.

Technological advancements emerge as a prominent trend reshaping the landscape of bone marrow transplantation. Key players in the healthcare sector are actively engaged in developing and introducing innovative technologies, aiming to fortify their market presence. An exemplar is the collaborative effort between BioIntelliSense and UC Davis Health in November 2023. Their joint initiative introduces continuous monitoring for bone marrow transplant patients, employing BioIntelliSense's FDA-cleared BioButton wearable devices coupled with algorithm-based data analytics. This proactive approach enables real-time detection of subtle changes in vital signs, facilitating timely interventions and informed clinical decisions for enhanced patient care.

Strategic partnerships have emerged as a driving force in augmenting access and broadening treatment options within the bone marrow transplantation industry. Companies are leveraging mutual strengths and resources through partnerships to achieve collective advancements. An illustrative partnership occurred in August 2023 between Ossium Health and Be the Match BioTherapies. This collaboration aims to bolster accessibility to bone marrow transplants and enhance treatment efficacy. By pooling resources, Ossium Health and Be the Match BioTherapies endeavor to extend life-saving treatments to a wider spectrum of patients, thereby significantly amplifying their reach and impact in the healthcare landscape.

In October 2024, Werfen, a medical diagnostics company based in Spain, acquired Omixon Bioinformatics Ltd. for $25 million. This acquisition is intended to expand Werfen's portfolio in transplant diagnostics, improving precision and efficiency in bone marrow transplantation processes to enhance patient outcomes. Omixon Bioinformatics Ltd., located in Hungary, specializes in transplant diagnostics and provides genetic and immunological testing solutions to ensure compatibility for organ and bone marrow transplants.

Major companies operating in the bone marrow transplantation market include Merck Millipore Corporation, Sanofi SA, STEMCELL Technologies Inc., HemaCare Corporation, AllCells LLC, Lonza Group Ltd., Conversant Bio Company, Lifeline Cell Technology LLC, Mesoblast Ltd., PromoCell GmbH, ATCC Inc. (American Type Culture Collection), Qiagen N.V., ReachBio LLC, Gamida Cell Ltd., Abbott Laboratories Inc., The Emmes Company LLC, Allogene Therapeutics Inc., Amgen Inc., Angiocrine Biosciences Corp., Astellas Pharma Inc., Atara Biotherapeutics Inc., Bluebird Bio Inc., Cellectis S.A., Celyad SA, Erythrocyte Regeneration and Clinical Therapeutics Inc., Gammacell AB, Gilead Sciences Inc., Graphite Bio Inc., Incyte Corporation, Intellia Therapeutics Inc., Legend Biotech Corporation, Magenta Therapeutics Inc., Novartis AG.

North America was the largest region in the bone marrow transplantation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global bone marrow transplantation market report forecast period. The regions covered in the bone marrow transplantation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bone marrow transplantation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bone marrow transplantation (BMT) is a specialized procedure used in treating individuals with specific malignancies or other conditions, involving the replacement of damaged or unhealthy bone marrow with healthy cells. This treatment is commonly employed for addressing blood cell disorders such as leukemia and lymphoma.

The primary categories of bone marrow transplantation include autologous bone marrow transplant and allogeneic bone marrow transplant. An autologous bone marrow transplant is a medical procedure focused on restoring stem cells that have been impaired by radiation or high doses of chemotherapy in a patient's own body. This type of transplant is indicated for various conditions such as Hodgkin lymphoma, acute leukemia, multiple myeloma, solid tumors, non-Hodgkin lymphoma, among others. These procedures are typically conducted in hospitals, multidisciplinary clinics, and ambulatory surgical centers.

The bone marrow transplantation market research report is one of a series of new reports that provides bone marrow transplantation market statistics, including bone marrow transplantation industry global market size, regional shares, competitors with a bone marrow transplantation market share, detailed bone marrow transplantation market segments, market trends and opportunities, and any further data you may need to thrive in the bone marrow transplantation industry. This bone marrow transplantation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bone marrow transplantation market includes revenues earned by providing transplantation services syngeneic transplants, allogeneic transplants, autologous transplants, haploidentical transplants, non-myeloablative transplants, and umbilical cord blood transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.